Your browser doesn't support javascript.
loading
The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt, Andrew M; Benson, Robert A; McQueenie, Ross; Butcher, John P; Braddock, Martin; Brewer, James M; McInnes, Iain B; Garside, Paul.
Afiliación
  • Platt AM; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • Benson RA; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • McQueenie R; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • Butcher JP; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • Braddock M; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • Brewer JM; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • McInnes IB; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK.
  • Garside P; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow and Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca Research and Development, Macclesfield, UK. paul.garside@glasgow.ac.uk.
Rheumatology (Oxford) ; 54(1): 169-77, 2015 Jan.
Article en En | MEDLINE | ID: mdl-25065010
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxazinas / Piridinas / Células Dendríticas / Proteínas Tirosina Quinasas / Linfocitos T CD4-Positivos / Péptidos y Proteínas de Señalización Intracelular Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxazinas / Piridinas / Células Dendríticas / Proteínas Tirosina Quinasas / Linfocitos T CD4-Positivos / Péptidos y Proteínas de Señalización Intracelular Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido